Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma

Boyle Eileen, Mary; Morschhauser, Franck

Document type :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1517/14740338.2015.1010505

PMID :

25716061

Permalink :

http://hdl.handle.net/20.500.12210/4280

Title :

Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma

Author(s) :

Boyle Eileen, Mary [Auteur]
Hôpital Claude Huriez [Lille]
Morschhauser, Franck [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]

Journal title :

Expert opinion on drug safety

Abbreviated title :

Expert Opin. Drug Saf.

Volume number :

Pages :

601-607

Publication date :

2015-04

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

INTRODUCTION: The current treatment approach of high-grade non-Hodgkin lymphoma (NHL) relies to a large extent on anthracycline-based regimens yielding cure rates in ∼ 65 - 75% of patients. Despite being highly effective, ...
Show more >INTRODUCTION: The current treatment approach of high-grade non-Hodgkin lymphoma (NHL) relies to a large extent on anthracycline-based regimens yielding cure rates in ∼ 65 - 75% of patients. Despite being highly effective, these regimens are associated with significant long-term toxicity with a cumulative 10-year incidence of cardiovascular disease of 22%. Moreover, for the 25 - 35% of patients who fail first-line therapy there has been very little progress in terms of salvage regimens over the past 15 years. Re-treatment with anthracyclines-based regimens was, until now, not an option given the extensive cardiac toxicity of these agents. Pixantrone dimaleate (Pixantrone) is a novel anthracycline-like drug that offers an interesting alternative for the treatment of aggressive NHL. AREAS COVERED: This article provides an overview of treatment-related cardiac toxicity in NHL, the pharmacology of Pixantrone and the evidence supporting its use in NHL. EXPERT OPINION: Pixantrone is a potential alternative agent with a favorable safety profile for the treatment of relapsed and refractory NHL patients. It might benefit from combinations strategies and further development in the elderly and frail population.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Research team(s) :

Innovation/évaluation des médicaments injectables

Submission date :

2019-02-26T17:03:57Z
2021-06-14T10:13:21Z

Version	Link	Modification date
2	20.500.12210/4280*	2021-06-14T09:52:01Z
1	20.500.12210/4280.1	2019-02-26T17:03:57Z

Pixantrone: a novel anthracycline-like ...

BibTeX

CSV

Excel

RIS

Version history

Pixantrone: a novel anthracycline-like ... BibTeX CSV Excel RIS

Version history

Pixantrone: a novel anthracycline-like ...

BibTeX

CSV

Excel

RIS